ESC 365 - Treatment of hypercholesterolaemia with PCSK-9 Inhibitors in Denmark. Assessment of real-life data; safety an extent of adverse effects after the first years of clinical use.

ESC Premium Access

Treatment of hypercholesterolaemia with PCSK-9 Inhibitors in Denmark. Assessment of real-life data; safety an extent of adverse effects after the first years of clinical use.

Session: Poster Session 1 - Preclinical pharmacotherapy

Topic: Lipid-Lowering Agents

Speaker: Doctor S. Mulverstedt (Copenhagen, DK)

Event: ESC Congress 2019

Congress Presentation

Add to my library

About the speaker

Doctor Stefan Mulverstedt

Bispebjerg University Hospital, Copenhagen (Denmark)

0 follower

8 more presentations in this session

The KCa2 channel inhibitor AP14145, but not dofetilide or ondansetron, provides functional atrial selectivity in guinea pig hearts

Speaker: Associate Professor N. Edvardsson (Gothenburg, SE)

Mechanisms of action of the small conductance Ca2+-activated K+-channel modulator AP30663, a novel compound being developed for treatment of atrial fibrillation in man

Speaker: Mrs S. Bomholtz (Copenhagen N, DK)

The SK channel inhibitor AP30663, converts vernakalant-resistant persistent AF and prevents its reinduction in pigs

Speaker: Doctor J. Diness (Copenhagen, DK)

The role of a phosphoinositide-3 kinase inhibitor in vascular inflammation

Speaker: Miss H. Chaudhry (London, GB)

Anti-thrombin nanoparticles for reduce vascular damage and promote functional recovery in acute ischemic kidney injury well after reperfusion

Speaker: Associate Professor H. Pan (Saint Louis, US)

Access the full session

Poster Session 1 - Preclinical pharmacotherapy

Speakers: Doctor S. Mulverstedt, Associate Professor N. Edvardsson, Mrs S. Bomholtz, Doctor J. Diness, Miss H. Chaudhry...

About the event

ESC Congress 2019

31 August - 4 September 2019

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources